12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Latuda lurasidone regulatory update

FDA accepted for review 2 sNDAs from Dainippon's Sunovion Pharmaceuticals Inc. subsidiary for Latuda lurasidone to treat adult patients with depressive episodes associated with bipolar I disorder as a monotherapy and as an adjunctive therapy to lithium...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >